Montano M M, Katzenellenbogen B S
Department of Molecular and Integrative Physiology, University of Illinois and College of Medicine, Urbana 61801-3704, USA.
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2581-6. doi: 10.1073/pnas.94.6.2581.
Antiestrogens are thought to exert most of their beneficial effects in breast cancer by antagonizing the actions of estrogen. We report here that antiestrogens also stimulate the expression of quinone reductase (QR) [NAD(P)H:quinone oxidoreductase, EC 1.6.99.2], which may provide protective effects against the toxicity and mutagenicity caused by quinones. QR is up-regulated by low concentrations of antiestrogens (trans-hydroxytamoxifen, tamoxifen, and ICI182,780) in estrogen receptor (ER)-containing breast cancer cells, and this increase is suppressed by estrogen via an ER-dependent mechanism. Since regulation of the QR gene, as well as other genes involved in detoxification such as the glutathione S-transferase Ya subunit (GST Ya) gene, is known to be mediated by an electrophile/antioxidant response element (EpRE/ARE), we examined the effects of antiestrogens on a 41-bp electrophile responsive region derived from the GST Ya gene. Transfection of this EpRE-containing region into ER-negative breast cancer cells in the presence or absence of an expression vector for the human ER, as well as mutagenesis studies, revealed that the EpRE-containing construct was activated by antiestrogen to the same extent as by tert-butylhydroquinone (TBHQ), a known activator of EpREs; however, only the stimulation by antiestrogen, and not TBHQ, required ER and was repressed by estradiol, although activation by both inducers mapped to the same 10-bp EpRE consensus sequence. Thus, there appear to be two pathways for QR induction, one that is activated by electrophile inducers such as TBHQ and is ER independent, and a second that is antiestrogen regulated and ER dependent; both pathways act through the EpRE. The anticancer action of antiestrogens may thus derive not only from the already well-known repression of estrogen-stimulated activities but also from the activation of detoxifying enzymes, such as QR, that may contribute to the beneficial antioxidant activity of antiestrogens.
抗雌激素药物被认为主要通过拮抗雌激素的作用在乳腺癌中发挥有益效果。我们在此报告,抗雌激素药物还能刺激醌还原酶(QR)[NAD(P)H:醌氧化还原酶,EC 1.6.99.2]的表达,这可能对醌类物质引起的毒性和致突变性起到保护作用。在含雌激素受体(ER)的乳腺癌细胞中,低浓度的抗雌激素药物(反式羟基他莫昔芬、他莫昔芬和ICI182,780)可上调QR的表达,而雌激素通过一种ER依赖机制抑制这种增加。由于已知QR基因以及其他参与解毒的基因(如谷胱甘肽S -转移酶Ya亚基(GST Ya)基因)的调控是由亲电试剂/抗氧化反应元件(EpRE/ARE)介导的,我们研究了抗雌激素药物对源自GST Ya基因的41个碱基对的亲电试剂反应区域的影响。将这个含EpRE的区域转染到ER阴性的乳腺癌细胞中,无论是否存在人ER的表达载体,以及进行诱变研究,结果表明含EpRE的构建体被抗雌激素药物激活的程度与已知的EpRE激活剂叔丁基对苯二酚(TBHQ)相同;然而,只有抗雌激素药物的刺激需要ER,并且会被雌二醇抑制,尽管两种诱导剂的激活都映射到相同的10个碱基对的EpRE共有序列。因此,似乎存在两种诱导QR的途径,一种由亲电试剂诱导剂(如TBHQ)激活且不依赖ER,另一种由抗雌激素药物调控且依赖ER;两种途径都通过EpRE起作用。抗雌激素药物的抗癌作用可能因此不仅源于其早已为人所知的对雌激素刺激活性的抑制,还源于解毒酶(如QR)的激活,这可能有助于抗雌激素药物有益的抗氧化活性。